Characteristics of heart rate variability in women with polycystic ovary syndrome

A retrospective cross-sectional study

Hae Ri Ji, MD (DKM) BS, Hye Lin Woo, MD (DKM) MS, Young Jae Park, MD (DKM) PhD, Deok Sang Hwang, MD (DKM) PhD, Jin Moo Lee, MD (DKM) PhD, Chang Hoon Lee, MD (DKM) PhD, Jun Bock Jang, MD (DKM) PhD, Kyoung Sun Park, MD (DKM) PhD

Abstract

We aimed to compare the modulation of the autonomic nervous system (ANS) in women with polycystic ovary syndrome (PCOS) with that in healthy ovulatory women on the basis of heart rate variability (HRV), and to analyze the characteristics of the ANS in PCOS.

In a retrospective chart review, HRV, body mass index, and physical examination data in women with PCOS and those with regular menstrual cycles were collected. Approval from the institutional review board (IRB) was obtained (IRB No. 2017-05-007-001) for this study. The mean outcomes were the values of HRV in the time [standard deviation of all normal R-R intervals (SDNN), the square root of the sum of the squares of the differences between the adjacent normal R-R intervals (rMSSD), and the mean heart rate turbulence (mean HRT)] and frequency [total power (TP), very-low-frequency power (VLF), low-frequency power (LF), normalized low-frequency power (LF norm), high-frequency power, mean high-frequency power (HF norm), and LF/HF ratio] domains. Differences between the 2 groups were analyzed by Mann-Whitney U test, using SPSS for Windows (version 22.0).

There was no significant difference in the values of the time domain (SDNN, rMSSD, and mean HRT) between the groups. In the frequency domain, women with PCOS showed significantly higher LF \( (89.63 \pm 94.38 \text{ vs } 459.13 \pm 163.64, P = 0.028) \), LF norm \( (48.64 \pm 3.39 \text{ vs } 36.49 \pm 2.82, P = 0.009) \), and LF/HF ratio \( (1.49 \pm 0.31 \text{ vs } 0.73 \pm 0.13, P = 0.009) \) than the control group. LF norm was significantly lower in the women with PCOS than in the controls \( (51.38 \pm 3.39 \text{ vs } 63.51 \pm 2.82, P = 0.009) \). The TP, VLF, and HF showed no significant difference between the groups.

The results of the present study indicated that PCOS is related to increased sympathetic modulation in HRV.

Abbreviations: ANS = autonomic nervous system, BMI = body mass index, BP = blood pressure, HF norm = normalized high-frequency power, HF = high-frequency power, HRV = heart rate variability, IRB = institutional review board, LF norm = normalized low-frequency power, LF = low-frequency power, mean HRT = mean heart rate turbulence, mRNA = messenger RNA, MSNA = muscle sympathetic nerve activity, PCO = polycystic ovaries, PCOS = polycystic ovary syndrome, rMSSD = the square root of the sum of the squares of the differences between the adjacent normal R-R intervals, SBP = systolic blood pressure, SDNN = mean of the standard deviation of all normal R-R intervals, SNS = sympathetic nervous system, TP = total power, VLF = very low-frequency power.

Keywords: autonomic nervous system, heart rate variability, polycystic ovary syndrome, sympathetic nervous system.

1. Introduction

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by menstrual dysfunction and infertility in reproductive-aged women. The clinical signs of the affected women include irregular menstrual cycle, increased androgens, hirsutism, and severe acne. In addition, metabolic disorders such as high insulin levels and risk of type II diabetes; cardiovascular diseases; and reproductive disorders such as increase in ovarian volume, lack of ovulation, and infertility have been reported.[1,2] PCOS is also associated with hypertension, dyslipidemia, and central obesity,[3,4] which are known to be related to sympathetic hyperactivity.[1,6] In recent years, the correlation between increased sympathetic activity and PCOS has been reported, as assessed by microneurography, the estimation of noradrenaline spillover, and heart rate variability (HRV).

The measurement of HRV has been widely used to evaluate the modulation of the autonomic nervous system (ANS), using cardiovascular function.[7,8] The sympathetic and parasympathetic modulation could be assessed by power spectral analysis of HRV. Diminished HRV, which indicates increased low-frequency power.
InBody 720 (Biospace Co, Ltd, Seoul, Korea), a practical and reliable
The recordings for height, weight, and BMI were obtained using
2.3. Measurement of BMI
normalized high-frequency power (HF norm), and LF/HF ratio.
 normalized low-frequency power (LF norm), HF (0.15
position for 5 minutes in a bright and silent room at 18
peroneal arteries in the ankle; they were placed in the supine
electrodes attached to both radial arteries in the wrist and
analyze the HRV. The participants were examined using
2.2. Measurement of HRV
was measured.
2.2. Measurement of HRV
HRV was recorded using SA-2000E (Medicore Co, Ltd, Seoul,
Korea), a practical and reliable device for measuring heart rate to
analyze the HRV. The participants were examined using electrodes
attached to both radial arteries in the wrist and peroneal arteries in the ankle; they were placed in the supine position for 5 minutes in a bright and silent room at 18°C to 23°C.
The time and frequency domains in the HRV were measured.
For the time domain, the mean of the standard deviation of all
normal R-R intervals (SDNN), the square root of the sum of the
differences of the adjacent normal R-R intervals (rMSSD), and the mean heart rate turbulence (mean HRT) were assessed. The values of the frequency domain were obtained at total power (TP: approximately ≤0.4 Hz), very low-frequency power (VLF: 0.003–0.04 Hz), LF (0.04–0.15 Hz), normalized low-frequency power (LF norm), HF (0.15–0.4 Hz), normalized high-frequency power (HF norm), and LF/HF ratio.
2.3. Measurement of BMI
The recordings for height, weight, and BMI were obtained using
InBody 720 (Biospace Co, Ltd, Seoul, Korea), a practical and reliable
device for measuring height, weight, and BMI. To obtain data on
BMI, the participants stayed still on the sole electrodes, grabbing the
hand electrodes simultaneously, for less than a minute.
2.4. Statistical analyses
The measured outcomes of the PCOS group and the controls
were statistically analyzed using SPSS version 22.0 for Windows
(SPSS Inc, Chicago, IL) and compared using Mann-Whitney U
test. The results were represented as the mean ± standard
deviation, and statistical significance was set at P < .05.
3. Results
3.1. Baseline characteristics of participants
The baseline clinical characteristics of the women with PCOS and
the control group are presented in Table 1. The 2 groups were
matched for age (P > .05). However, significant differences in
BMI and BP were observed between the groups. Women with
PCOS showed higher BMI, systolic blood pressure (SBP), and
diastolic blood pressure than the control group.
3.2. Time domain in HRV
The results of the time domains in the HRV analysis for the
women with PCOS and the control group are shown in Table 2. There was no significant difference in the values of SDNN,
rMSSD, and mean HRT between the groups.
3.3. Frequency domain in HRV
The values of the frequency domains in the HRV analysis for the
PCOS group and the control group are presented in Figure 1. The
TP, VLF, and HF showed no significant differences between the
groups. However, women with PCOS showed significantly higher LF (598.63 ± 94.38 vs 459.13 ± 163.64, P = .028), LF norm (48.64 ± 3.39 vs 36.49 ± 2.82, P = .009), and LF/HF ratio (1.49 ± 0.31 vs 0.73 ± 0.13, P = .009) than women in the control group. The HF norm was significantly lower in women with
PCOS than in the controls (51.38 ± 3.39 vs 63.51 ± 2.82, P = .009).
4. Discussion
PCOS is a common endocrine disorder that induces menstrual
dysfunction and infertility. The exact etiology of PCOS is
unknown, and it affects approximately 5% to 10% of
reproductive-aged women worldwide. PCOS is diagnosed when 2 of the following 3 criteria are present: hyperandrogenism (clinical or biochemical), oligo/amenorrhea, and appearance of polycystic ovaries (PCOs) on ultrasound, according to the Rotterdam PCOS diagnostic criteria.[12] PCOS is characterized by reproductive sequelae, such as oligo/anovulation, hyperandrogenism (either clinical or biochemical), and altered ovarian morphology, as well as endocrine features, including central obesity, hyperinsulinemia, insulin resistance, dyslipidemia,[14] and hypertension.[15] The common features of PCOS, namely increased insulin resistance and adiposity, have been known to correlate with sympathetic hyperactivity,[16] which suggests that sympathoexcitation could be associated with the pathogenesis of PCOS. Several methods have been developed to measure the ANS. These include microneurography, estimation of noradrenaline spillover, and HRV. There is no single criterion standard method for assessing the ANS. Among these methods, HRV has been frequently used in clinical situations owing to its viability and noninvasiveness. HRV, a statistical measure of the heart rate, is frequently used in clinical situations owing to its viability and noninvasiveness. The results of our study indicated that women with PCOS had increased alpha-1 adrenoceptor messenger RNA (mRNA) and decreased alpha-2 adrenoceptor mRNA (a sympathoinhibitory receptor), which is interpreted as increased sympathetic activity. According to Luza et al.[18] rats with PCO showed increased noradrenergic activity in the anterior hypothalamic nerve terminals. Furthermore, Lara et al[17] showed that intraovarian synthesis of the nerve growth factor, associated with the modulation of the sympathetic nervous system (SNS), increased in rats with PCO.

In addition, women with PCOS tend to show a generalized increase in the activity of the SNS, which could increase the ovarian sympathetic activity. The increase of sympathetic activity in PCOS was investigated by measuring catecholamine and its metabolites in previous studies. It was observed that women with PCOS reportedly had decreased urinary 3-methoxy-4-hydroxyphenylglycol,[18,19] which is consistent with noradrenergic excess. Recently, the muscle sympathetic nerve activity (MSNA) and postexercise SBP have been used to measure the modulation of the SNS. According to Sverrisdottir et al,[20] women with PCOS have higher MSNA, which is a direct measure of the SNS, than their age- and BMI-matched controls. Tekin et al[21] showed that women with PCOS showed higher SBP response to exercise, which is accompanied by a continued sympathetic stimulation.

Limited studies have assessed the function of the ANS in women with PCOS on the basis of HRV. Yildirir et al[11] and Lee et al[10] reported that the PCOS group had significantly higher LF norm and lower HF norm than the controls. Contrary to the abovementioned studies, De Sá et al[9] reported that women with PCOS showed significantly lower LF and HF than the controls. The results of our study indicated that women with PCOS had significantly higher LF, LF norm, and LF/HF ratio than the controls. Meanwhile, HF norm was significantly lower in women with PCOS than in the controls. These results are in line with those of the studies conducted by Yildirir et al[11] and Lee et al[10] which suggested that women with PCOS had increased sympathetic activity and decreased parasympathetic modulation in HRV, with reference to higher LF and LF/HF ratio and a lower HF.

### Table 2

|                | PCOS (n = 32) | Control (n = 32) | P     |
|----------------|---------------|-----------------|-------|
| SDNN, ms²     | 50.12 ± 3.12  | 48.68 ± 5.57    | .297  |
| rMSSD, ms²    | 43.19 ± 3.20  | 45.63 ± 3.29    | .581  |
| Mean HRT, ms² | 68.09 ± 1.50  | 68.59 ± 1.70    | .860  |

SDNN = heart rate turbulence, PCOS = polycystic ovary syndrome, rMSSD = square root of the sum of the square of the difference between the adjacent normal R-R intervals, SDNN = standard deviation of all normal R-R intervals. Statistically significant by Mann-Whitney U test.

Figure 1. Heart rate variability values of the frequency domain in the PCOS group (n=35) and the control group (n=32). A = TP, B = VLF, C = LF, D = HF, E = LF norm, F = HF norm, G = LF/HF ratio, HF = high frequency power, HF norm = normalized high frequency power, LF = low frequency power, LF norm = normalized low frequency power, LF/HF ratio = low frequency power-to-high frequency power ratio, PCOS = polycystic ovary syndrome, TP = total power, VLF = very low-frequency power. Statistically significant by Mann-Whitney U test (P < .05, **P < .01).
A limitation of our study is the imbalance of BMI and BP between the groups. In addition, HRV assessment was not conducted on a specific day of the menstrual cycle of the participants. Although the results of this study support that sympathetic modulation may be increased in women with PCOS, further investigation is required to determine whether an imbalance of BMI and BP between the groups affects the HRV. Individuals with high BP tend to have decreased HRV,[12,23] however, the influence of BMI on HRV has been controversial.[24,25] Hence, the effects of BMI and BP on the results of HRV in our study are difficult to evaluate. Therefore, further studies including a BMI- and BP-matched control group are warranted. Despite the controversy regarding menstrual cycle and HRV outcomes,[26–28] menstrual cycle-controlled analyses are also required.

5. Conclusion
In the present study, LF, LF norm, and LF/HF ratio were found to be significantly higher in the PCOS group than in the control group, whereas HF norm was significantly lower in the PCOS group. Thus, we can propose that sympathetic modulation may be increased in women with PCOS. Further studies with a BMI- and BP-matched control group are warranted to analyze the characteristics of ANS in PCOS.

Author contributions
HRJ and KSP contributed to the study concept and design. HRJ performed the statistical analyses and wrote the original draft. YJP, JML, CHL, and KSP contributed to the acquisition of data. All authors were responsible for interpretation of the results and critical revision of the manuscript, and approved the final manuscript.

Supervision: Kyoung Sun Park.

Writing – original draft: Hae Ri Ji.

Writing – review and editing: Hye Lin Woo, Young Jae Park, Deok Sang Hwang, Jin Moo Lee, Chang Hoon Lee, Jun Bock Jang, Kyoung Sun Park.

References
[1] Majumdar A, Singh TA. Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome. J Hum Reprod Sci 2009;2:12–7.
[2] Vahedi M, Saeedi A, Poorbaghi SL, et al. Metabolic and endocrine effects of bisphenol A exposure in market seller women with polycystic ovary syndrome. Environ Sci Pollut Res Int 2016;23:23546–50.
[3] Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet 2007;370:685–97.
[4] Weeraket S, Srisombut C, Bunnag P, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001;75:177–84.
[5] Flaa A, Aknes TA, Kjeldsen SE, et al. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism 2008;57:1422–7.
[6] Alvarez GE, Beske SD, Ballard TP, et al. Sympathetic neural activation in visceral obesity. Circulation 2002;106:2533–6.
[7] Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043–65.
[8] Kleger RE, Stein PK, Bigger JT. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005;10:88–101.
[9] De Sá JCF, Costa RC, Sa Silva E, et al. Analysis of heart rate variability in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:443–7.
[10] Lee MJ, Hwang DS, Lee JM, et al. A study on oriental medicine diagnostic application through analysis of heart rate variability in polycystic ovary syndrome females. J Korean Obster Gynecol 2010;23:153–63.
[11] Yıldırır A, Aybar F, Kabakci G, et al. Heart rate variability in young women with polycystic ovary syndrome. Ann Noninvasive Electrocardiol 2006;11:306–12.
[12] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.
[13] Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–6.
[14] Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:623–9.
[15] Stener-Victorin E, Ploj K, Larson BM, et al. Rats with steroid-induced polycystic ovaries develop hypertension and increased sympathetic nervous system activity. Reprod Biol Endocrinol 2005;3:44.
[16] Luza S, Lizama L, Burgos R, et al. Hypothalamic changes in norepinephrine release in rats with estradiol valerate-induced polycystic ovaries. Biol Reprod 1995;52:398–404.
[17] Lara H, Diesen G, Leyton V, et al. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000;141:1039–72.
[18] Shoupe D, Lobo RA. Evidence for altered catecholamine metabolism in polycystic ovary syndrome. Am J Obstet Gynecol 1984;150:566–71.
[19] Yoshino K, Takahashi K, Nishigaki A, et al. Further evidence concerning catecholamine metabolism in polycystic ovary syndrome following GnRH administration. Int J Fertil 1992;37:111–4.
[20] Sverrisdottir YB, Mogren T, Kataoka J, et al. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008;294:E576–81.
[21] Tekin G, Tekin A, Kılçarslan EB, et al. Altered autonomic neural control of the cardiovascular system in patients with polycystic ovary syndrome. Int J Cardiol 2008;130:49–55.
[22] Schroeder EB, Liao D, Chambless LE, et al. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension 2003;42:1106–11.
[23] Singh JP, Larson MG, Tsuji H, et al. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 1998;32:293–7.
[24] Karason K, Mølgaard H, Wikstrand J, et al. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999;83:1242–7.
[25] Antelmi I, De Paula RS, Shinzato AR, et al. Effects of menstrual cycle on cardiac autonomic innervation as assessed by heart rate variability. Ann Noninvasive Electrocardiol 2002;7:60–3.
[26] Lecht AS, Hirning DA, Allen GD. Heart rate variability and endogenous sex hormones during the menstrual cycle in young women. Exp Physiol 2003;88:441–6.
[27] Princi T, Parco S, Accardo A, et al. Parametric evaluation of heart rate variability during the menstrual cycle in young women. Biomed Sci Instrum 2005;41:340–5.